Ana Gimeno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Gimeno has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Jesús Jiménez-Barbero
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain
21 shared publications - Ana Ardá
CIC bioGUNE, Bizkaia Science & Technology Park , bld 800, 48160 Derio, Bizkaia
8 shared publications Sandra Delgado
Center for Cooperative Research in Biosciences (CIC bioGUNE)
6 shared publications- June Ereño-Orbea
Cancer Glycoimmunology Laboratory Center for Cooperative Research in Biosciences (CIC bioGUNE) Basque Research and Technology Alliance (BRTA) Derio Spain
4 shared publications - Filipa Marcelo
UCIBIO – Applied Molecular Biosciences Unit Department of Chemistry NOVA School of Science and Technology NOVA University Lisbon Caparica Portugal
3 shared publications - Francisco Corzana
Universidad de La Rioja
3 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Wiley in ChemBioChem
- Vol. 27 (19) , e70552
Encoding Cell‐Surface Receptor Function Through Glycosylation: Lessons From CD44
Cell surface receptors are traditionally conceptualized as discrete molecular entities whose functional diversity arises primarily from gene expression and protein sequence variation. However, this view overlooks the extensive heterogeneity generated by post‐translational modifications, particularly glycosylation, which can profoundly alter receptor structure, dynamics, and interactions. Increasing evidence suggests that glycosylation does not simply fine‐tune receptor activity but rather defines distinct functional receptor states by modulating ligand recognition, nanoscale organization, interaction networks, and signaling competence. Among glycosylated receptors, CD44 provides a particularly informative model due to its extensive alternative splicing, dense glycosylation, and well‐characterized interactions with the extracellular matrix. CD44 exhibits remarkable structural and functional plasticity and regulates diverse biological processes ranging from cell adhesion and migration to inflammation and cancer progression. Importantly, glycosylation influences CD44 interactions with its principal ligand, hyaluronan, as well as its ability to cluster, engage coreceptors, and initiate downstream signaling pathways. In this review, we discuss how glycosylation regulates CD44 function across multiple levels, from molecular recognition to membrane organization and signaling. Using CD44 as a paradigmatic example, we explore how glycosylation may shape distinct aspects of receptor function, underscoring its importance as a fundamental determinant of receptor biology and its relevance for therapeutic targeting.
- 9 October 2026
- Published by Wiley in ChemBioChem
- Vol. 27 (19) , e70552
Open AccessEncoding Cell‐Surface Receptor Function Through Glycosylation: Lessons From CD44
Cell surface receptors are traditionally conceptualized as discrete molecular entities whose functional diversity arises primarily from gene expression and protein sequence variation. However, this view overlooks the extensive heterogeneity generated by post‐translational modifications, particularly glycosylation, which can profoundly alter receptor structure, dynamics, and interactions. Increasing evidence suggests that glycosylation does not simply fine‐tune receptor activity but rather defines distinct functional receptor states by modulating ligand recognition, nanoscale organization, interaction networks, and signaling competence. Among glycosylated receptors, CD44 provides a particularly informative model due to its extensive alternative splicing, dense glycosylation, and well‐characterized interactions with the extracellular matrix. CD44 exhibits remarkable structural and functional plasticity and regulates diverse biological processes ranging from cell adhesion and migration to inflammation and cancer progression. Importantly, glycosylation influences CD44 interactions with its principal ligand, hyaluronan, as well as its ability to cluster, engage coreceptors, and initiate downstream signaling pathways. In this review, we discuss how glycosylation regulates CD44 function across multiple levels, from molecular recognition to membrane organization and signaling. Using CD44 as a paradigmatic example, we explore how glycosylation may shape distinct aspects of receptor function, underscoring its importance as a fundamental determinant of receptor biology and its relevance for therapeutic targeting.
- Open Access
- 1 October 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (10) , 5744-5756
Glycosylation Encodes Selective Galectin Recognition and Signaling by Osteopontin
Post-translational modifications critically regulate extracellular molecular recognition, yet their roles in intrinsically disordered proteins remain poorly defined. Here, we integrate glycoproteomics, NMR, and cellular assays to reveal how glycosylation shapes the interaction network of osteopontin (OPN), a highly glycosylated intrinsically disordered protein. We show that OPN displays a heterogeneous repertoire of predominantly sialylated O-glycans that drive selective lectin binding: galectin-3 preferentially binds terminal LacNAc-containing epitopes, whereas galectin-8 engages multiple sialylated and sulfated glycan motifs, promoting cross-linking of OPN. In contrast, binding to CD44 receptor is largely glycosylation-independent and is mediated primarily through the polypeptide backbone. This dual recognition mechanism enables OPN to act as a molecular scaffold that couples glycan-mediated galectin binding with CD44 receptor engagement. Consistent with this proposed mechanistic model, OPN/galectin complexes are recruited to CD44-expressing cells where glycosylated OPN suppresses galectin-8-induced apoptosis, whereas deglycosylated OPN does not. Together, our results reveal that glycosylation encodes interaction specificity and downstream signaling outcomes in an intrinsically disordered extracellular protein, establishing OPN as a paradigm for how glycans organize extracellular recognition networks.
- 1 October 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (10) , 5744-5756
Open AccessGlycosylation Encodes Selective Galectin Recognition and Signaling by Osteopontin
Post-translational modifications critically regulate extracellular molecular recognition, yet their roles in intrinsically disordered proteins remain poorly defined. Here, we integrate glycoproteomics, NMR, and cellular assays to reveal how glycosylation shapes the interaction network of osteopontin (OPN), a highly glycosylated intrinsically disordered protein. We show that OPN displays a heterogeneous repertoire of predominantly sialylated O-glycans that drive selective lectin binding: galectin-3 preferentially binds terminal LacNAc-containing epitopes, whereas galectin-8 engages multiple sialylated and sulfated glycan motifs, promoting cross-linking of OPN. In contrast, binding to CD44 receptor is largely glycosylation-independent and is mediated primarily through the polypeptide backbone. This dual recognition mechanism enables OPN to act as a molecular scaffold that couples glycan-mediated galectin binding with CD44 receptor engagement. Consistent with this proposed mechanistic model, OPN/galectin complexes are recruited to CD44-expressing cells where glycosylated OPN suppresses galectin-8-induced apoptosis, whereas deglycosylated OPN does not. Together, our results reveal that glycosylation encodes interaction specificity and downstream signaling outcomes in an intrinsically disordered extracellular protein, establishing OPN as a paradigm for how glycans organize extracellular recognition networks.
- 8 September 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (44) , 48042-48053
Noncarbohydrate Inhibitors of Sialic Acid-Binding Immunomodulatory-Type Lectin-7 (Siglec-7) Discovered from Genetically Encoded Bicyclic Peptide Libraries
Glycan-binding proteins (GBPs) are among the most difficult drug targets, limiting clinical progress against therapeutically important GBPs. We employed bicyclic genetically encoded libraries (BiGELs), produced by the chemical modification of phage-displayed peptide libraries with twofold symmetric linchpins, to discover inhibitors of therapeutically relevant Siglec-7:GD3 interactions. Next-generation sequencing (NGS) analysis of BiGEL panning against Siglec-7 yielded 815 candidates, of which 23 hits yielded KD = 1–100 μM, as determined by surface plasmon resonance (SPR). Competitive enzyme-linked immunosorbent assays (ELISA) identified leads that disrupted the Siglec-7:GD3 interaction with IC50 = 3-300 μM. Machine learning models trained on NGS datasets identified additional inhibitors with equivalent potencies. Alanine scans of 8c (SWCRPATVNC, IC50 = 3.8 μM) and 12c (SFCHYPTHVC, IC50 = 11 μM) identified residues crucial for activity. Ring reshaping studies of 8c highlighted the critical role of bicyclic topology, yielding analog 46e (SAAAAAWCRPATVNC, IC50 = 9.5 μM), which was further evolved into 67e (STVTQHWCRPATVNC). The multivalent display of lead bicycles alongside ∼100 glycans in a Liquid Glycan Array (LiGA) enabled the comparison of binding to Siglec-7-expressing cells. LiGA assays confirmed the binding of the bicycles to Siglec-7 but revealed considerable nonspecific interactions with receptor-negative cells. Saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy revealed that 46e binds to Siglec-7 at a site distinct from the V-Ig domain, suggesting inhibition through an allosteric site. Together, these results demonstrate that BiGEL enables the discovery of bicyclic peptides for undruggable Siglec targets, but highlights future challenges in molecular discoveries that aim to identify small, noncarbohydrate inhibitors of GBPs.
- 8 September 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (44) , 48042-48053
Noncarbohydrate Inhibitors of Sialic Acid-Binding Immunomodulatory-Type Lectin-7 (Siglec-7) Discovered from Genetically Encoded Bicyclic Peptide Libraries
Glycan-binding proteins (GBPs) are among the most difficult drug targets, limiting clinical progress against therapeutically important GBPs. We employed bicyclic genetically encoded libraries (BiGELs), produced by the chemical modification of phage-displayed peptide libraries with twofold symmetric linchpins, to discover inhibitors of therapeutically relevant Siglec-7:GD3 interactions. Next-generation sequencing (NGS) analysis of BiGEL panning against Siglec-7 yielded 815 candidates, of which 23 hits yielded KD = 1–100 μM, as determined by surface plasmon resonance (SPR). Competitive enzyme-linked immunosorbent assays (ELISA) identified leads that disrupted the Siglec-7:GD3 interaction with IC50 = 3-300 μM. Machine learning models trained on NGS datasets identified additional inhibitors with equivalent potencies. Alanine scans of 8c (SWCRPATVNC, IC50 = 3.8 μM) and 12c (SFCHYPTHVC, IC50 = 11 μM) identified residues crucial for activity. Ring reshaping studies of 8c highlighted the critical role of bicyclic topology, yielding analog 46e (SAAAAAWCRPATVNC, IC50 = 9.5 μM), which was further evolved into 67e (STVTQHWCRPATVNC). The multivalent display of lead bicycles alongside ∼100 glycans in a Liquid Glycan Array (LiGA) enabled the comparison of binding to Siglec-7-expressing cells. LiGA assays confirmed the binding of the bicycles to Siglec-7 but revealed considerable nonspecific interactions with receptor-negative cells. Saturation transfer difference nuclear magnetic resonance (STD-NMR) spectroscopy revealed that 46e binds to Siglec-7 at a site distinct from the V-Ig domain, suggesting inhibition through an allosteric site. Together, these results demonstrate that BiGEL enables the discovery of bicyclic peptides for undruggable Siglec targets, but highlights future challenges in molecular discoveries that aim to identify small, noncarbohydrate inhibitors of GBPs.
- Open Access
- 29 December 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (1) , 82-94
Presentation Is Essential for Glycan-Lectin Recognition at the Molecular and Cellular Levels: The Interaction of Tumor-Associated O -Glycans with the Macrophage Galactose-Type Lectin
The human macrophage galactose-type lectin (MGL) recognizes exposed GalNAc residues abundantly found in tumor O-glycans. Herein, we have used an integrative chemical, structural, and functional approach to unravel the intricate specificity and molecular determinants that underlie the recognition of Thomsen-nouveau (Tn), the sialylated variant (STn), and Thomsen-Friedenreich (TF) O-glycans by the carbohydrate recognition domain of the MGL (MGL-CRD) at the molecular and cellular levels. The MGL-CRD prefers binding to Tn > STn ≫ TF O-glycans. In this molecular context, NMR, isothermal titration calorimetry, and molecular dynamics simulations revealed quantitative key structural and dynamic differences in binding, depending on the O-glycan. Interestingly, the density of Tn epitopes was critical for engaging multiple MGL-CRDs to MUC1 Tn-glycopeptides; however, the enthalpy–entropy balance strongly influenced the affinity, and a higher Tn density did not improve the binding. Cell-based mucin arrays recapitulated the MGL-CRD binding preference (Tn > STn ≫TF), but no preference for a specific O-glycan pattern in mucins was observed. The MGL-CRD also selectively recognizes glycoengineered gastric cancer cells expressing Tn/STn. Conversely, in the cellular context, employing CHO cells expressing the full-length MGL (CHO+MGL) allowed analysis of the MGL binding properties in its native presentation toward tagged isolated mucin reporters. Specificity for short tumor-associated O-glycans without any preference for a specific mucin was confirmed. Stunningly, the CHO+MGL cells revealed that the MGL shows similar binding to the STn and TF mucin reporters, suggesting that its natural oligomeric state displays promiscuous binding to simple O-glycans. Conceptually, the key role of glycan and lectin presentations for binding is thus highlighted. Moreover, this suggests the compelling scenario that the MGL serves as a universal receptor for truncated cancer-associated O-glycans.
- 29 December 2025
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6 (1) , 82-94
Open AccessPresentation Is Essential for Glycan-Lectin Recognition at the Molecular and Cellular Levels: The Interaction of Tumor-Associated O -Glycans with the Macrophage Galactose-Type Lectin
The human macrophage galactose-type lectin (MGL) recognizes exposed GalNAc residues abundantly found in tumor O-glycans. Herein, we have used an integrative chemical, structural, and functional approach to unravel the intricate specificity and molecular determinants that underlie the recognition of Thomsen-nouveau (Tn), the sialylated variant (STn), and Thomsen-Friedenreich (TF) O-glycans by the carbohydrate recognition domain of the MGL (MGL-CRD) at the molecular and cellular levels. The MGL-CRD prefers binding to Tn > STn ≫ TF O-glycans. In this molecular context, NMR, isothermal titration calorimetry, and molecular dynamics simulations revealed quantitative key structural and dynamic differences in binding, depending on the O-glycan. Interestingly, the density of Tn epitopes was critical for engaging multiple MGL-CRDs to MUC1 Tn-glycopeptides; however, the enthalpy–entropy balance strongly influenced the affinity, and a higher Tn density did not improve the binding. Cell-based mucin arrays recapitulated the MGL-CRD binding preference (Tn > STn ≫TF), but no preference for a specific O-glycan pattern in mucins was observed. The MGL-CRD also selectively recognizes glycoengineered gastric cancer cells expressing Tn/STn. Conversely, in the cellular context, employing CHO cells expressing the full-length MGL (CHO+MGL) allowed analysis of the MGL binding properties in its native presentation toward tagged isolated mucin reporters. Specificity for short tumor-associated O-glycans without any preference for a specific mucin was confirmed. Stunningly, the CHO+MGL cells revealed that the MGL shows similar binding to the STn and TF mucin reporters, suggesting that its natural oligomeric state displays promiscuous binding to simple O-glycans. Conceptually, the key role of glycan and lectin presentations for binding is thus highlighted. Moreover, this suggests the compelling scenario that the MGL serves as a universal receptor for truncated cancer-associated O-glycans.
- Open Access
Non-Carbohydrate Inhibitors of Sialic Acid-binding Immunomodulatory-type Lectin-7 (Siglec-7) Discovered from Genetically Encoded Bicyclic Peptide Libraries
Glycan-binding proteins (GBP) are among the most difficult to drug targets. This deficiency delays clinical progress for therapeutically important GBPs. We employed bicyclic genetically encoded libraries (BiGELs), produced by chemical modification of phage-displayed libraries of peptides with two-fold symmetric linchpins, to discover inhibitors of therapeutically relevant Siglec-7:GD3 interactions. Next-generation sequencing (NGS) analysis of panning of BiGEL against Siglec-7 yielded 815 candidates from which 23 hits yielded K D = 1−100 µM as determined by surface plasmon resonance (SPR). Competitive enzyme-linked immunosorbent assays (ELISA) identified a subset of leads that disrupted the Siglec-7:GD3 interaction with IC 50 = 3−300 µM. Machine learning models trained on NGS datasets identified additional inhibitors with equivalent potency. Alanine scans of 8c (SWCRPATVNC, IC 50 = 3.8 µM) and 12c (SFCHYPTHVC, IC 50 = 11 µM), identified key residues as crucial for activity. Ring reshaping studies of compound 8c highlighted the critical role of bicyclic topology produced by analogue 46e (SAAAAAWCRPATVNC, IC 50 = 9.5 µM). Multivalent display of the lead bicycles alongside ∼100 glycans in Liquid glycan Array (LiGA), made it possible to compare the binding of bicycles and glycans to Siglec-7 expressed on CHO, Jurkat, and Raji cells. LiGA assays confirmed binding of the bicycles to Siglec-7 but revealed considerable non-specific interactions with receptor-negative cells. Saturation transfer difference nuclear magnetic resonance (STD-NMR) revealed 46e binds to Siglec-7 at a site distinct from the V-Ig domain, suggesting it might inhibit binding of glycans to the glycan-binding site of Siglec-7 via an allosteric site. Together these results demonstrate that BiGEL enables the discovery of bicyclic peptides for undruggable Siglec targets but highlights future challenges in molecular discoveries that aim to identify small, non-carbohydrate inhibitors of GBPs.
Open AccessNon-Carbohydrate Inhibitors of Sialic Acid-binding Immunomodulatory-type Lectin-7 (Siglec-7) Discovered from Genetically Encoded Bicyclic Peptide Libraries
Glycan-binding proteins (GBP) are among the most difficult to drug targets. This deficiency delays clinical progress for therapeutically important GBPs. We employed bicyclic genetically encoded libraries (BiGELs), produced by chemical modification of phage-displayed libraries of peptides with two-fold symmetric linchpins, to discover inhibitors of therapeutically relevant Siglec-7:GD3 interactions. Next-generation sequencing (NGS) analysis of panning of BiGEL against Siglec-7 yielded 815 candidates from which 23 hits yielded K D = 1−100 µM as determined by surface plasmon resonance (SPR). Competitive enzyme-linked immunosorbent assays (ELISA) identified a subset of leads that disrupted the Siglec-7:GD3 interaction with IC 50 = 3−300 µM. Machine learning models trained on NGS datasets identified additional inhibitors with equivalent potency. Alanine scans of 8c (SWCRPATVNC, IC 50 = 3.8 µM) and 12c (SFCHYPTHVC, IC 50 = 11 µM), identified key residues as crucial for activity. Ring reshaping studies of compound 8c highlighted the critical role of bicyclic topology produced by analogue 46e (SAAAAAWCRPATVNC, IC 50 = 9.5 µM). Multivalent display of the lead bicycles alongside ∼100 glycans in Liquid glycan Array (LiGA), made it possible to compare the binding of bicycles and glycans to Siglec-7 expressed on CHO, Jurkat, and Raji cells. LiGA assays confirmed binding of the bicycles to Siglec-7 but revealed considerable non-specific interactions with receptor-negative cells. Saturation transfer difference nuclear magnetic resonance (STD-NMR) revealed 46e binds to Siglec-7 at a site distinct from the V-Ig domain, suggesting it might inhibit binding of glycans to the glycan-binding site of Siglec-7 via an allosteric site. Together these results demonstrate that BiGEL enables the discovery of bicyclic peptides for undruggable Siglec targets but highlights future challenges in molecular discoveries that aim to identify small, non-carbohydrate inhibitors of GBPs.
- Open Access
Molecular basis of Siglec-10 ligand recognition and antibody blockade
Siglec-10 is a sialic acid-binding immunoglobulin-like lectin implicated in immune regulation, yet the molecular basis for ligand recognition and how this is functionally linked to immune modulation remains poorly defined. Herein, we present a multidisciplinary study encompassing structural, biochemical, and cellular approaches to elucidate Siglec-10-carbohydrate interactions and their functional consequences. The crystal structure of the extracellular domain of Siglec-10 in complex with α2-6 sialyllactose revealed the presence of two key arginine residues within the Siglec-10 binding site that interact with the carboxyl group of sialic acid, the canonical R119 and R127, suggesting potential dual contributions to ligand engagement. Saturation Transfer Difference (STD)-Nuclear Magnetic Resonance (NMR) confirmed that R119 is essential for sialoglycan binding in solution, whereas R127 appears dispensable for interactions with glycans under these conditions. In contrast, cell-based binding assays using primary human T cells and engineered monocytic lines demonstrated that both arginine residues (R119 and R127) are critical for cellular recognition, revealing a context-dependent interaction. By obtaining direct images at a molecular resolution of 6-7 nm, super-resolution microscopy further revealed glycan-independent dimerization of the Siglec-10 receptor on the surface of human monocytes. Ligand blockade mediated by anti-Siglec-10 mAb (clone S10A) restores CAR-T cell cytotoxicity in vitro , supporting its role as an immune checkpoint receptor. Finally, although CD24 was not identified as a Siglec-10 ligand on T cells, proximity labeling and mass spectrometry uncovered other sialylated glycoproteins that may mediate this interaction. Together, these results identify Siglec-10 as a modulatory receptor with structural and functional features distinct from other Siglec family members and highlight its potential for therapeutic targeting in cancer immunotherapy.
Open AccessMolecular basis of Siglec-10 ligand recognition and antibody blockade
Siglec-10 is a sialic acid-binding immunoglobulin-like lectin implicated in immune regulation, yet the molecular basis for ligand recognition and how this is functionally linked to immune modulation remains poorly defined. Herein, we present a multidisciplinary study encompassing structural, biochemical, and cellular approaches to elucidate Siglec-10-carbohydrate interactions and their functional consequences. The crystal structure of the extracellular domain of Siglec-10 in complex with α2-6 sialyllactose revealed the presence of two key arginine residues within the Siglec-10 binding site that interact with the carboxyl group of sialic acid, the canonical R119 and R127, suggesting potential dual contributions to ligand engagement. Saturation Transfer Difference (STD)-Nuclear Magnetic Resonance (NMR) confirmed that R119 is essential for sialoglycan binding in solution, whereas R127 appears dispensable for interactions with glycans under these conditions. In contrast, cell-based binding assays using primary human T cells and engineered monocytic lines demonstrated that both arginine residues (R119 and R127) are critical for cellular recognition, revealing a context-dependent interaction. By obtaining direct images at a molecular resolution of 6-7 nm, super-resolution microscopy further revealed glycan-independent dimerization of the Siglec-10 receptor on the surface of human monocytes. Ligand blockade mediated by anti-Siglec-10 mAb (clone S10A) restores CAR-T cell cytotoxicity in vitro , supporting its role as an immune checkpoint receptor. Finally, although CD24 was not identified as a Siglec-10 ligand on T cells, proximity labeling and mass spectrometry uncovered other sialylated glycoproteins that may mediate this interaction. Together, these results identify Siglec-10 as a modulatory receptor with structural and functional features distinct from other Siglec family members and highlight its potential for therapeutic targeting in cancer immunotherapy.
- Open Access
- 16 December 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (1) , 225-236
Decoding the Molecular Basis of the Specificity of an Anti-sTn Antibody
The mucin O-glycan sialyl Tn antigen (sTn, Neu5Acα2-6GalNAcα1-O-Ser/Thr) is an antigen associated with different types of cancers, often linked with a higher risk of metastasis and poor prognosis. Despite efforts to develop anti-sTn antibodies with high specificity for diagnostics and immunotherapy, challenges in eliciting high-affinity antibodies for glycan structures have limited their effectiveness, leading to low titers and short protection durations. Experimental structural insights into anti-sTn antibody specificity are lacking, hindering their optimization for cancer cell recognition. In this study, we used a comprehensive structural approach, combining X-ray crystallography, NMR spectroscopy, computational methods, glycan/glycopeptide microarrays, and biophysical techniques, to thoroughly investigate the molecular basis of sTn recognition by L2A5, a novel preclinical anti-sTn monoclonal antibody (mAb). Our data unequivocally show that the L2A5 fragment antigen-binding (Fab) specifically binds to core sTn moieties. NMR and X-ray structural data suggest a similar binding mode for the complexes formed by the sTn moiety linked to Ser or Thr and the L2A5 Fab. The sugar moieties are similarly oriented in the paratope of mAb, with the Neu5Ac moiety establishing key interactions with the receptor and the GalNAc moiety providing additional contacts. Furthermore, L2A5 exhibits fine specificity toward cancer-related MUC1 and MUC4 mucin-derived sTn glycopeptides, which might contribute to its selective targeting against tumor cells. This newfound knowledge holds promise for the rational improvement and potential application of this anti-sTn antibody in diagnosis and targeted therapy against sTn expressing cancers such as breast, colorectal, and bladder cancer, improving patient care.
- 16 December 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 5 (1) , 225-236
Open AccessDecoding the Molecular Basis of the Specificity of an Anti-sTn Antibody
The mucin O-glycan sialyl Tn antigen (sTn, Neu5Acα2-6GalNAcα1-O-Ser/Thr) is an antigen associated with different types of cancers, often linked with a higher risk of metastasis and poor prognosis. Despite efforts to develop anti-sTn antibodies with high specificity for diagnostics and immunotherapy, challenges in eliciting high-affinity antibodies for glycan structures have limited their effectiveness, leading to low titers and short protection durations. Experimental structural insights into anti-sTn antibody specificity are lacking, hindering their optimization for cancer cell recognition. In this study, we used a comprehensive structural approach, combining X-ray crystallography, NMR spectroscopy, computational methods, glycan/glycopeptide microarrays, and biophysical techniques, to thoroughly investigate the molecular basis of sTn recognition by L2A5, a novel preclinical anti-sTn monoclonal antibody (mAb). Our data unequivocally show that the L2A5 fragment antigen-binding (Fab) specifically binds to core sTn moieties. NMR and X-ray structural data suggest a similar binding mode for the complexes formed by the sTn moiety linked to Ser or Thr and the L2A5 Fab. The sugar moieties are similarly oriented in the paratope of mAb, with the Neu5Ac moiety establishing key interactions with the receptor and the GalNAc moiety providing additional contacts. Furthermore, L2A5 exhibits fine specificity toward cancer-related MUC1 and MUC4 mucin-derived sTn glycopeptides, which might contribute to its selective targeting against tumor cells. This newfound knowledge holds promise for the rational improvement and potential application of this anti-sTn antibody in diagnosis and targeted therapy against sTn expressing cancers such as breast, colorectal, and bladder cancer, improving patient care.
- Open Access
- 9 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (50) , 34452-34465
Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals
Glycosylation is an attractive approach to enhance biological properties of pharmaceutical proteins; however, the precise installation of glycans for structure-function studies remains challenging. Here, we describe a chemoenzymatic methodology for glyco-tagging of proteins by peptidoligase catalyzed modification of the N-terminus of a protein with a synthetic glycopeptide ester having an N-acetyl-glucosamine (GlcNAc) moiety to generate an N-GlcNAc modified protein. The GlcNAc moiety can be elaborated into complex glycans by trans-glycosylation using well-defined sugar oxazolines and mutant forms of endo β-N-acetylglucosaminidases (ENGases). The glyco-tagging methodology makes it possible to modify on-demand therapeutic proteins, including heterologous proteins expressed in E. coli, with diverse glycan structures. As a proof of principle, the N-terminus of interleukin (IL)-18 and interferon (IFN)α-2a was modified by a glycopeptide harboring a complex N-glycan without compromising biological potencies. The glyco-tagging methodology was also used to prepare several glycosylated insulin variants that exhibit reduced oligomerization, aggregation, and fibrillization yet maintained cell signaling properties, which are attractive for the development of insulins with improved shelf-lives. It was found that by employing different peptidoligases, it is possible to modify either the A or both chains of human insulin.
- 9 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (50) , 34452-34465
Open AccessSite-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals
Glycosylation is an attractive approach to enhance biological properties of pharmaceutical proteins; however, the precise installation of glycans for structure-function studies remains challenging. Here, we describe a chemoenzymatic methodology for glyco-tagging of proteins by peptidoligase catalyzed modification of the N-terminus of a protein with a synthetic glycopeptide ester having an N-acetyl-glucosamine (GlcNAc) moiety to generate an N-GlcNAc modified protein. The GlcNAc moiety can be elaborated into complex glycans by trans-glycosylation using well-defined sugar oxazolines and mutant forms of endo β-N-acetylglucosaminidases (ENGases). The glyco-tagging methodology makes it possible to modify on-demand therapeutic proteins, including heterologous proteins expressed in E. coli, with diverse glycan structures. As a proof of principle, the N-terminus of interleukin (IL)-18 and interferon (IFN)α-2a was modified by a glycopeptide harboring a complex N-glycan without compromising biological potencies. The glyco-tagging methodology was also used to prepare several glycosylated insulin variants that exhibit reduced oligomerization, aggregation, and fibrillization yet maintained cell signaling properties, which are attractive for the development of insulins with improved shelf-lives. It was found that by employing different peptidoligases, it is possible to modify either the A or both chains of human insulin.
- Open Access
- 16 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Unprecedented selectivity for homologous lectin targets: differential targeting of the viral receptors L-SIGN and DC-SIGN
DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently. DC-SIGN, found in dendritic cells, shapes the immune response by recognizing pathogen-associated carbohydrate patterns. In contrast, L-SIGN, expressed in airway epithelial endothelial cells, is not directly involved in immunity. COVID-19’s primary threat is the hyperactivation of the immune system, potentially reinforced if DC-SIGN engages with exogenous ligands. Therefore, L-SIGN, co-localized with ACE2-expressing cells in the respiratory tract, is a more suitable target for anti-adhesion therapy. However, designing a selective ligand for L-SIGN is challenging due to the high sequence identity of the Carbohydrate Recognition Domains (CRDs) of the two lectins. We here present Man84, a mannose ring modified with a methylene guanidine triazole at position 2. It binds L-SIGN with a KD of 12.7 μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group’s role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84’s conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.
- 16 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessUnprecedented selectivity for homologous lectin targets: differential targeting of the viral receptors L-SIGN and DC-SIGN
DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently. DC-SIGN, found in dendritic cells, shapes the immune response by recognizing pathogen-associated carbohydrate patterns. In contrast, L-SIGN, expressed in airway epithelial endothelial cells, is not directly involved in immunity. COVID-19’s primary threat is the hyperactivation of the immune system, potentially reinforced if DC-SIGN engages with exogenous ligands. Therefore, L-SIGN, co-localized with ACE2-expressing cells in the respiratory tract, is a more suitable target for anti-adhesion therapy. However, designing a selective ligand for L-SIGN is challenging due to the high sequence identity of the Carbohydrate Recognition Domains (CRDs) of the two lectins. We here present Man84, a mannose ring modified with a methylene guanidine triazole at position 2. It binds L-SIGN with a KD of 12.7 μM ± 1 μM (ITC) and is the first known L-SIGN selective ligand, showing 50-fold selectivity over DC-SIGN (SPR). The X-ray structure of the L-SIGN CRD/Man84 complex reveals the guanidinium group’s role in achieving steric and electrostatic complementarity with L-SIGN. This allows us to trace the source of selectivity to a single amino acid difference between the two CRDs. NMR analysis confirms the binding mode in solution, highlighting Man84’s conformational selection upon complex formation. Dimeric versions of Man84 achieve additional selectivity and avidity in the low nanomolar range. These compounds selectively inhibit L-SIGN dependent trans-infection by SARS-CoV-2 and Ebola virus. Man84 and its dimeric constructs display the best affinity and avidity reported to date for low-valency glycomimetics targeting CLRs. They are promising tools for competing with SARS-CoV-2 anchoring in the respiratory tract and have potential for other medical applications.
- 29 September 2021
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 16 (11) , 2481-2489
Sulfation Code and Conformational Plasticity of l-Iduronic Acid Homo-Oligosaccharides Mimic the Biological Functions of Heparan Sulfate
Recently, the activity of heparan sulfate (HS) has led to the discovery of many drug candidates that have the potential to impact both medical science and human health. However, structural diversity and synthetic challenges impede the progress of HS research. Here, we report a library of novel l-iduronic acid (IdoA)-based HS mimics that are highly tunable in conformation plasticity and sulfation patterns to produce many of the functions of native HS oligosaccharides. The NMR analysis of HS mimics confirmed that 4-O-sulfation enhances the population of the 1C4 geometry. Interestingly, the 1C4 conformer becomes exclusive upon additional 2-O-sulfation. HS mimic microarray binding studies with different growth factors showed that selectivity and avidity are greatly modulated by the oligosaccharide length, sulfation code, and IdoA conformation. Particularly, we have identified 4-O-sulfated IdoA disaccharide (I-21) as a potential ligand for vascular endothelial growth factor (VEGF165), which in a multivalent display modulated endothelial cell proliferation, migration, and angiogenesis. Overall, these results encourage the consideration of HS mimics for therapeutic applications.
- 29 September 2021
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 16 (11) , 2481-2489
Sulfation Code and Conformational Plasticity of l-Iduronic Acid Homo-Oligosaccharides Mimic the Biological Functions of Heparan Sulfate
Recently, the activity of heparan sulfate (HS) has led to the discovery of many drug candidates that have the potential to impact both medical science and human health. However, structural diversity and synthetic challenges impede the progress of HS research. Here, we report a library of novel l-iduronic acid (IdoA)-based HS mimics that are highly tunable in conformation plasticity and sulfation patterns to produce many of the functions of native HS oligosaccharides. The NMR analysis of HS mimics confirmed that 4-O-sulfation enhances the population of the 1C4 geometry. Interestingly, the 1C4 conformer becomes exclusive upon additional 2-O-sulfation. HS mimic microarray binding studies with different growth factors showed that selectivity and avidity are greatly modulated by the oligosaccharide length, sulfation code, and IdoA conformation. Particularly, we have identified 4-O-sulfated IdoA disaccharide (I-21) as a potential ligand for vascular endothelial growth factor (VEGF165), which in a multivalent display modulated endothelial cell proliferation, migration, and angiogenesis. Overall, these results encourage the consideration of HS mimics for therapeutic applications.